BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17962723)

  • 1. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
    Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
    Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
    Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
    Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
    Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
    Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
    Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma.
    Curry BJ; Farrelly M; Hersey P
    Melanoma Res; 1999 Dec; 9(6):557-67. PubMed ID: 10661766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers to detect metastatic uveal melanoma.
    Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
    Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
    Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
    Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
    Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
    J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
    Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
    Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
    Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
    Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
    Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.